Urological disorders immunotherapeutic - AmVac

Drug Profile

Urological disorders immunotherapeutic - AmVac

Alternative Names: AMV 110; ProstaVac

Latest Information Update: 29 May 2015

Price : $50

At a glance

  • Originator Vakcina Kft
  • Developer AmVac
  • Class Bacterial vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Benign prostatic hyperplasia; Prostatitis

Most Recent Events

  • 29 May 2015 No recent reports on development identified - Phase-II for Benign prostatic hyperplasia and Prostatitis in Hungary (IM)
  • 29 Feb 2012 AmVac's immunotherapeutic for urological disorders is available for partnering in USA, Japan. http://amvac.eu/v2/
  • 05 Feb 2007 Phase-II clinical trials in Prostatitis in Hungary (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top